Tankyrase inhibition in cancer immunotherapy
Purpose:
The aim of this study is to assess efficacy of and mechanism-of-action behind monotherapy with WNT/tankyrase inhibitors and in combination therapy with checkpoint inhibitors against solid tumors. Previously performed mouse experiments have clearly documented the benefit of WNT/tankyrase inhibitor and checkpoint inhibitor combination treatment of cancer.
Expected injury: Subcutanous tumors cause moderate discomfort and all involved drug treatments are well tolerated by mice. Benefit: The experiments will create a functional and mechanistic basis for the use of tankyrase inhibitors in phase I clinical trial against several cancers in patients, -in particular for melanoma.
Experiment size: The experimental setup involves the use of a total of 272 inbred mus musculus, details of the various strains are further specified in the designated section of the application.
3R compliance: Group sizes are kept at a minimum required for statistically firm conclusions.
The aim of this study is to assess efficacy of and mechanism-of-action behind monotherapy with WNT/tankyrase inhibitors and in combination therapy with checkpoint inhibitors against solid tumors. Previously performed mouse experiments have clearly documented the benefit of WNT/tankyrase inhibitor and checkpoint inhibitor combination treatment of cancer.
Expected injury: Subcutanous tumors cause moderate discomfort and all involved drug treatments are well tolerated by mice. Benefit: The experiments will create a functional and mechanistic basis for the use of tankyrase inhibitors in phase I clinical trial against several cancers in patients, -in particular for melanoma.
Experiment size: The experimental setup involves the use of a total of 272 inbred mus musculus, details of the various strains are further specified in the designated section of the application.
3R compliance: Group sizes are kept at a minimum required for statistically firm conclusions.